Tissue factor pathway inhibitor is the main determinant of thrombin generation in haemophilic patients.


Journal

Haemophilia : the official journal of the World Federation of Hemophilia
ISSN: 1365-2516
Titre abrégé: Haemophilia
Pays: England
ID NLM: 9442916

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 24 05 2018
revised: 14 12 2018
accepted: 14 12 2018
pubmed: 29 1 2019
medline: 30 4 2019
entrez: 29 1 2019
Statut: ppublish

Résumé

The thrombin generation (TG) assay evaluates haemostatic balance, which is influenced by the levels of many coagulation factors and inhibitors. Our objective was to identify the determinant factors of TG in haemophilia A (HA) and haemophilia B (HB) patients and to compare them to those in healthy controls. Coagulation factor and inhibitor levels, and TG, were measured in platelet-poor plasma from 40 patients with HA, 32 patients with HB and 40 healthy subjects. Data were analysed using multiple regression models. In HA patients, factor VIII was a positive determinant of endogenous thrombin potential (ETP) and peak, whereas tissue factor pathway inhibitor (TFPI) and factor V were negative determinants of ETP and peak. In HB patients, FIX was a positive determinant of ETP and peak, FVII being a positive determinant of peak. Antithrombin and protein S (PS) were negative determinants of ETP while FX was a negative determinant of peak. Above all, in HB patients, TFPI was a negative determinant of ETP and peak. In healthy subjects, FVIII was a positive determinant of ETP and peak, whereas FX and protein S were negative determinants of these parameters. TFPI was not a negative determinant of either peak or ETP. In haemophilic patients, the determinant factors of TG are all implicated in FXa generation and inhibition, the crucial determinant factor being TFPI whatever the type of haemophilia, A or B. These findings contribute to the rationale that recently place TFPI as a target for innovative therapies of haemophilia.

Identifiants

pubmed: 30690836
doi: 10.1111/hae.13679
doi:

Substances chimiques

Blood Coagulation Factors 0
Lipoproteins 0
lipoprotein-associated coagulation inhibitor 0
Fibrinogen 9001-32-5
Thrombin EC 3.4.21.5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

343-348

Subventions

Organisme : Pfizer
ID : WI193434

Informations de copyright

© 2019 John Wiley & Sons Ltd.

Auteurs

Pierre Chelle (P)

CIS-EMSE, SAINBIOSE, Ecole Nationale Supérieure des Mines de Saint-Etienne, Saint Etienne, France.
INSERM, U1059, SAINBIOSE, Université de Lyon, UJM-Saint-Etienne, Saint-Etienne, France.

Aurélie Montmartin (A)

INSERM, U1059, SAINBIOSE, Université de Lyon, UJM-Saint-Etienne, Saint-Etienne, France.

Pauline Damien (P)

INSERM, CIC 1408, FCRIN-INNOVTE, CHU Saint-Etienne, Saint-Etienne, France.

Michèle Piot (M)

INSERM, U1059, SAINBIOSE, Université de Lyon, UJM-Saint-Etienne, Saint-Etienne, France.

Michel Cournil (M)

CIS-EMSE, SAINBIOSE, Ecole Nationale Supérieure des Mines de Saint-Etienne, Saint Etienne, France.
INSERM, U1059, SAINBIOSE, Université de Lyon, UJM-Saint-Etienne, Saint-Etienne, France.

Anne Lienhart (A)

Centre de référence et de traitement de l'hémophilie, Hopital Cardiologique Louis Pradel, Lyon, France.

Fabienne Genre-Volot (F)

Centre de traitement de l'hémophilie, CHU Bocage, Dijon, France.

Hervé Chambost (H)

Centre de traitement de l'hémophilie, Hôpital d'enfants La Timone, Marseille, France.

Claire Morin (C)

CIS-EMSE, SAINBIOSE, Ecole Nationale Supérieure des Mines de Saint-Etienne, Saint Etienne, France.

Brigitte Tardy-Poncet (B)

INSERM, U1059, SAINBIOSE, Université de Lyon, UJM-Saint-Etienne, Saint-Etienne, France.
INSERM, CIC 1408, FCRIN-INNOVTE, CHU Saint-Etienne, Saint-Etienne, France.
Centre de traitement de l'hémophilie, CHU Saint-Etienne, Saint-Etienne, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH